Research Projects

Large non-coding RNAs and microRNAs are important regulators of gene expression that may control both physiological and pathological processes such as neurodegenerative disorders. Given the complexity of neurodegenerative disorders, studying the role of non-coding RNAs would be necessary to understand the molecular mechanisms underlying ageing...

Brain disorders impose an increasing economical and social burden in the member states of the European Union (EU). For most neurodegenerative diseases and many neuropsychiatric disorders no efficient treatment is available and no cure exists. In the next coming years the number of particularly elderly people suffering from brain disorders will...

At present more than 5 million people in the EU suffer from dementia and other neurodegenerative diseases and that number will grow as the average age of the population continues to increase. The efficacy of current medicines is limited and new therapeutic targets are sorely needed. Several independent lines of evidence have established an...

Stroke-caused cognitive and neuromotor impairment is currently an increasing burden: post-stroke deficits are commonly believed to be treated with rehabilitation. Direct medical costs of stroke are stimated to increase up to 94.3 billion USD only in US. The indirect costs, including non-healthcare costs, are estimated at 15.9 billion. The journey...

The project develops an integrated theratainment solution for care, rehab and diagnostics. PLAYTIME motivates in a playful manner to perform personalized emotion-oriented exercise units to stimulate cognitive processes, to address physical activities and foster social inclusion. The objective is to motivate dementia users to enter a positive...

Alzheimer’s disease (AD) and related disorders leading to dementia are associated with staggering costs and suffering. Recently, there has been some progress in the search for effective therapeutic interventions and it is clear that any treatment is likely to be most effective if administered at the earliest stage of disease, but the health care...

PHARMA-COG aims to develop a new integrated model to accelerate the development of drug candidates for MS, PKD and AD. The innovation relies on a 'multidimensional matrix' approach, integrating all available and renewed inputs (biomarkers/animal, human models/physiological and pharmacological challenges, Phase 0/1/1b to reduce the attrition rate...

COMFORTAGE is a joint effort of medical experts (i.e., neurologists, psychiatrists, neuropsychologists, nurses, memory clinics), social scientists and humanists, technical experts (i.e., data scientists, AI experts, robotic experts) and Digital Innovation Hubs to establish a pan European framework for Community-based, Integrated and People-Centric...

PRIME introduces the novel concept of insulin signalling as a key mechanism underlying the multimorbidity of major mental and somatic illnesses. It is well known that aberrant insulin signalling causes high health and socioeconomic burden through its role in diabetes, metabolic syndrome, and obesity. We posit that the impact of ‘insulinopathies’ is...

Alzheimer’s disease (AD) is the leading cause of dementia and loss of autonomy in the elderly, implying a progressive cognitive decline and limitation of social activities. Progressive aging of EU population will increase the magnitude of this problem in the next decades. Currently, there is not an effective method for the early diagnosis of AD...

The current nosology of neuropsychiatric disorders allows for a pragmatic approach to treatment choice, regulation and clinical research. However, without a biological rationale for these disorders, drug development has dramatically stagnated in the past decades. In a coordinated effort encompassing academic experts, SMEs, patient and family...

The overall prevalence of brain disorders – both neurological and psychiatric – is very high in Europe. Although it is well known that the burden and costs of these disorders are high, there is evidence that the overall, personal, social and economic costs of brain disorders have been underestimated because of the lack of valid and reliable...